Maine Institute For Human Genetics and Health
Executive Director
Aastrom Biosciences Jan 2002 - Oct 2006
Vice President Global Research, Chief Scientific Officer
University of Indiana Medical and Dental Schools Jan 2000 - Sep 2004
Professor
Eli Lilly and Company 1992 - 2000
Director, Skeletal Diseases Research
Echoing Air
Member of Board of Directors
Faseb 2012 - 2016
Asbmr Representative on Editorial Board
The Polis Center at Iupui 2012 - 2016
Senior Scholar
Indianapolis Symphonic Choir 2012 - 2016
Member, Indianapolis Symphonic Choir
Indianapolis Shakespeare Company 2012 - 2016
Company Member
Education:
University of London 1970 - 1974
Doctorates, Doctor of Philosophy, Medicine
Caltech 1972 - 1973
University of Iowa College of Dentistry 1970 - 1972
University of Iowa College of Dentistry 1968 - 1970
Master of Science, Masters, Medicine
University of Illinois School of Medicine 1967 - 1968
Skills:
Cell Culture Clinical Research Cancer Cell Molecular Biology Biotechnology Cell Biology Translational Research Oncology Life Sciences Lifesciences Genomics R&D Neuroscience Science Drug Development Flow Cytometry Biobanking Laboratory Direct Multidisciplinary Research Teams
Janet M. Hock - Indianapolis IN, US Gregory A. Gaich - Indianapolis IN, US Willard H. Dere - Westlake Village Ventura CA, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K038/29 C07K014/635
US Classification:
4241981, 514 12, 530324
Abstract:
The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracure, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
Method Of Increasing Bone Toughness And Stiffness And Reducing Fractures
Gregory A. Gaich - Indianapolis IN, US Willard H. Dere - Westlake Village Ventura CA, US Janet M. Hock - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/29 C07K 14/635
US Classification:
4241981, 514 12, 530324
Abstract:
The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
Gregory A. Gaich - Indianapolis IN, US Willard H. Dere - Westlake Village Ventura CA, US Janet M. Hock - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/29 C07K 14/635
US Classification:
4241981, 514 12, 530324
Abstract:
The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fractur and/or reduce the incidence of non-vertebral fracture.
Micro Rna (Mirna) And Neurofibromatosis Type 1: A Role In Diagnosis And Therapy
Xijie Yu - Orono ME, US Janet M. Hock - Bangor ME, US
Assignee:
Maine Institute of Human Genetics and Health - Brewer ME
International Classification:
A61K 48/00
US Classification:
514 44R
Abstract:
The present invention shows that levels of certain micro RNAs (MiRNAs) are altered in NF1 cell lines and NF1 tumor cell lines as compared to non-NF1 controls. Methods are provided, e. g. , to diagnose NF1 and NF1 tumors. Methods are also provided to treat NF1, NF1 related cancer, and cognitive deficits resulting from NF1.
Method Of Increasing Bone Toughness And Stiffness And Reducing Fractures
Janet Hock - Indianapolis IN, US Gregory Gaich - Indianapolis IN, US Willard Dere - Carmel IN, US
International Classification:
A61K038/29
US Classification:
514/012000
Abstract:
The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
Methods for decreasing the risk of cancer by administering a parathyroid hormone are disclosed. More particularly, the disclosed methods are for decreasing the risk of cancer in a person at risk of developing cancer, including persons at relatively low risk of osteoporosis, or at high risk of or suffering from osteoporosis. The methods are particularly effective for decreasing risks of breast or skin carcinoma.
Method For Monitoring Treatment With A Parathyroid Hormone
Janet Hock - Indianapolis IN, US Julie Satterwhite - Zionsille IN, US
International Classification:
A61K031/198 C12Q001/42
US Classification:
435021000, 514567000
Abstract:
The present invention relates to a method for monitoring effects of administration of a parathyroid hormone by determining levels of one or more markers of an activity of this hormone. Suitable markers of bone formation include one or more enzymes indicative of osteoblastic processes of bone formation, preferably bone specific alkaline phosphatase, and/or one or more products of collagen biosynthesis, preferably a procollagen I C-terminal propetide. Suitable markers of bone resorption and turnover include one or more products of collagen degradation, preferably an N-terminal telopeptide (NTX). In addition, methods for concurrently reducing the risk of both vertebral and non-vertebral bone fracture in a male human subject at risk of or having ossteoporosis are also disclosed, involving administration of human parathyroid hormone (amino acid sequence 1-34) without concurrent administration of an antiseropositive agent other than vitamin D or calcium.
Method Of Increasing Bone Toughness And Stiffness And Reducing Fractures
Gregory Gaich - Indianapolis IN, US Willard Dere - Westlake Village Ventura CA, US Janet Hock - Indianapolis IN, US
International Classification:
A61K 38/29
US Classification:
514002000
Abstract:
The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.